Therapeutic Strategies Targeting Glioblastoma Stem Cells
- Authors: Estefania Carrasco Garcia1, Nicolas Sampron2,3, Paula Aldaz4, Olatz Arrizabalaga5, Jorge Villanua6,7, Cristina Barrena8,9, Irune Ruiz10,11, Mariano Arrazola12,13, Charles Lawrie14, Ander Matheu15
-
View Affiliations Hide Affiliations1 Neuroncology Group, Biodonostia Institute, Paseo Dr. Begiristain s/n, E- 20014 San Sebastian, Spain 2 Neuroncology Group, Biodonostia Institute, Paseo Dr. Begiristain s/n, E- 20014 San Sebastian, Spain 3 Neurosurgery Service, Donostia Hospital, Paseo Dr. Begiristain s/n, E-20014 San Sebastian, Spain 4 Neuroncology Group, Biodonostia Institute, Paseo Dr. Begiristain s/n, E- 20014 San Sebastian, Spain 5 Neuroncology Group, Biodonostia Institute, Paseo Dr. Begiristain s/n, E- 20014 San Sebastian, Spain 6 Neuroncology Group, Biodonostia Institute, Paseo Dr. Begiristain s/n, E- 20014 San Sebastian, Spain 7 Neurosurgery Service, Donostia Hospital, Paseo Dr. Begiristain s/n, E-20014 San Sebastian, Spain 8 Neuroncology Group, Biodonostia Institute, Paseo Dr. Begiristain s/n, E- 20014 San Sebastian, Spain 9 Neurosurgery Service, Donostia Hospital, Paseo Dr. Begiristain s/n, E-20014 San Sebastian, Spain 10 Neuroncology Group, Biodonostia Institute, Paseo Dr. Begiristain s/n, E- 20014 San Sebastian, Spain 11 Neurosurgery Service, Donostia Hospital, Paseo Dr. Begiristain s/n, E-20014 San Sebastian, Spain 12 Neuroncology Group, Biodonostia Institute, Paseo Dr. Begiristain s/n, E- 20014 San Sebastian, Spain 13 Neurosurgery Service, Donostia Hospital, Paseo Dr. Begiristain s/n, E-20014 San Sebastian, Spain 14 Head Oncology Department, Biodonostia Institute, Paseo Dr. Begiristain s/n, E-20014 San Sebastian, Spain 15 Neuroncology Group, Biodonostia Institute, Paseo Dr. Begiristain s/n, E- 20014 San Sebastian, Spain
- Source: Topics in Anti-Cancer Research: Volume 3 , pp 151-178
- Publication Date: October 2014
- Language: English
Therapeutic Strategies Targeting Glioblastoma Stem Cells, Page 1 of 1
< Previous page | Next page > /docserver/preview/fulltext/9781608059089/chapter-4-1.gif
Glioblastoma is the most common, aggressive and lethal brain tumor in adults. However, current therapeutic protocols have low success rates, and average overall survival is less than 15 months. The resistance to therapy is largely a result of the remarkable cellular and phenotypical heterogeneity that characterizes this type of tumor. The discovery of a subpopulation of cells exhibiting stem cell properties within the tumor bulk has profound implications for therapy as increasing evidence indicates that these cells, glioblastoma stem cells (GSCs), are responsible for the origin, maintenance and recurrence of the glioblastomas. These findings highlight the need to characterize GSCs in order to find novel treatments directly targeted specifically against them. In this chapter, we summarize the current knowledge regarding this issue, including some recent and relevant patents.
-
From This Site
/content/books/9781608059089.chapter-4dcterms_subject,pub_keyword-contentType:Journal -contentType:Figure -contentType:Table -contentType:SupplementaryData105
